Ocuphire Pharma

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that clinical data from its ZETA-1 trial evaluating APX3330 in diabetic retinopathy (DR) on a validated binocular person-level scale was presented yesterday at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place May 5-9, 2024 in Seattle, Washington. The presentation, titled Oral APX3330, a Ref-1 Inhibitor, Slows Progression of Diabetic Retinopathy on a Binocular DRSS Person-Level Scale, was delivered by Daniel Su, M.D., a practicing retina specialist at Retina-Vitreous Associates Medical Group (LA Retina) in Los Angeles, California.

Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A., M.S., Chief Executive Officer of Ocuphire, will present a company overview at the Aegis Virtual Conference being held May 7-9, 2024. Company management will also be participating in one-on-one meetings throughout the conference.

Ocuphire Pharma to Present at the Aegis Virtual Conference

FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that Daniel Su, M.D. will deliver a paper presentation on oral APX3330 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5-9, 2024 in Seattle, Washington.

Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the enrollment of the first subject in the LYNX-2 Phase 3 registration study evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery.

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS).

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

Arcturus Therapeutics

Incyte

Jazz Pharmaceuticals

United Therapeutics

Veracyte

Voyager Therapeutics

While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A, M.S. CEO of Ocuphire, will be presenting a company overview at the BIO CEO & Investor Conference being held February 26-27 2024 in New York City. Company management will also be participating in one-on-one meetings throughout the conference.

Ocuphire Pharma to Present in the BIO CEO & Investor Conference

FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved equity awards under Ocuphire's 2021 Inducement Plan, as a material inducement to Ashwath Jayagopal, Ph.D., M.B.A., the Company's newly appointed Chief Scientific and Development Officer and to Nirav Jhaveri, C.F.A.., M.B.A., the Company's newly appointed Chief Financial Officer in connection with their employment with the Company effective on February 12, 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A.

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

Himax Tech

With the U.S. economy running at full steam and the labor market continuing to impress onlookers, the concept of value stocks might not be the most popular idea. After all, many of the usual suspects of 2023 are still printing strong returns.

3 Value Stocks to Buy on the Dip: February 2024

FARMINGTON HILLS, Mich., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that clinical data from its ZETA-1 trial on a person-level scale evaluating APX3330 in diabetic retinopathy (DR) were presented at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference, which took place virtually on Saturday, February 3, 2024. The presentation, titled APX3330 Oral Treatment to Slow the Progression of Diabetic Retinopathy Using a Binocular DRSS Severity Scale as a Registrational Endpoint, was delivered by Veeral Sheth, M.D., M.B.A., a practicing retina specialist at University Retina, and Clinical Assistant Professor at the University of Illinois.

Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference

Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.

Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now

Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024 Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024

Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions

Ocuphire Pharma, Inc. (NASDAQ:OCUP ) Corporate Update Call December 5, 2023 10:00 AM ET Company Participants Dr. George Magrath - Chief Executive Officer Michael Wood - LifeSci Advisors Charlie Hoffmann - SVP of Corporate Development Ronil Patel - Chief Business Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald John Newman - Canaccord Genuity Operator Greetings. Welcome to Ocuphire Pharma Incorporated Corporate Update Call with CEO Dr. George Magrath.

Ocuphire Pharma, Inc. (OCUP) Ocuphire Pharma Corporate Update Call (Transcript)

Ocuphire Pharma, Inc. (OCUP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bears are Losing Control Over Ocuphire Pharma, Inc. (OCUP), Here's Why It's a 'Buy' Now

Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023 Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023

Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

D-MARKET Electronic Services

Power Solutions

After a rocky couple of years, there finally seems to be some light at the end of the tunnel for growth stocks. Interest rates have stabilized, and the economy is again showing signs of strength.

Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024

FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved an equity award under Ocuphire's 2021 Inducement Plan, as a material inducement to Joseph K. Schachle, the Company's newly appointed Chief Operating Officer, in connection with his employment with the Company effective on November 27, 2023. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate and Commercial Operations Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate and Commercial Operations

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Successful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI ™ Approved by FDA; Ocuphire Received $10 million Regulatory Milestone Payment VEGA-2 Phase 3 Presbyopia Trial Met Primary Endpoint; Viatris Expected to Continue Phase 3 Development in 1H 2024 George Magrath, M.D., M.B.A., M.S.

Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

Agreement on Phase 3 Primary Endpoint of 3-step Worsening on Binocular Diabetic Retinopathy Severity Scale (DRSS) Score

Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy

Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development

Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S.

FARMINGTON HILLS, Mich., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced presentations featuring APX3330 and phentolamine ophthalmic solution at the American Academy of Ophthalmology Annual Meeting (AAO 2023) to take place in San Francisco, California on November 3-6, 2023. In addition, Jay Pepose, M.D. Ph.D., Chief Medical Advisor at Ocuphire, will provide a corporate overview at the Eyecelerator AAO 2023 Retina Showcase in San Francisco, California on November 2, 2023.

Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase

Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy

News for Ocuphire Pharma Stock (OCUP)